| Literature DB >> 31681289 |
Kelvin M Kimenyi1,2, Kevin Wamae1, Lynette Isabella Ochola-Oyier1,3.
Abstract
Malaria is still a significant public health burden in the tropics. Infection with malaria causing parasites results in a wide range of clinical disease presentations, from severe to uncomplicated or mild, and in the poorly understood asymptomatic infections. The complexity of asymptomatic infections is due to the intricate interplay between factors derived from the human host, parasite, and environment. Asymptomatic infections often go undetected and provide a silent natural reservoir that sustains malaria transmission. This creates a major obstacle for malaria control and elimination efforts. Numerous studies have tried to characterize asymptomatic infections, unanimously revealing that host immunity is the underlying factor in the maintenance of these infections and in the risk of developing febrile malaria infections. An in-depth understanding of how host immunity and parasite factors interact to cause malaria disease tolerance is thus required. This review primarily focuses on understanding anti-inflammatory and pro-inflammatory responses to asymptomatic infections in malaria endemic areas, to present the view that it is potentially the shift in host immunity toward an anti-inflammatory profile that maintains asymptomatic infections after multiple exposures to malaria. Conversely, symptomatic infections are skewed toward a pro-inflammatory immune profile. Moreover, we propose that these infections can be better interrogated using next generation sequencing technologies, in particular RNA sequencing (RNA-seq), to investigate the immune system using the transcriptome sampled during a clearly defined asymptomatic infection.Entities:
Keywords: RNA-seq; asymptomatic infection; cytokines; immunity; malaria
Mesh:
Year: 2019 PMID: 31681289 PMCID: PMC6803459 DOI: 10.3389/fimmu.2019.02398
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Examples of inclusion criteria used to define asymptomatic individuals in transcriptomic studies.
| Cameroon, 2009 | Positive thick blood smear and afebrile. No history of fever and antimalarial treatment in the previous 1 and 2 weeks, respectively, at the time of mass screening | Children <12 years ( | No follow-up | ( |
| Mali, 2011 | PCR-detected | Individuals >13 ( | Bi-weekly and weekly surveillance for | ( |
| Gabon, 2005 | Thin and thick blood smear and no clinical symptoms | Children 0.5–6 years (ND) | Follow up for 5 consecutive days | ( |
| Uganda, 2007–2008 | Blood smear and no fever | Children 4–5 years ( | Follow up for 7 days | ( |
| Mali, 2006 | Not defined | 5–13 years ( | Healthy baseline before the malaria season, 7 or 14 days after treatment of their first malaria episode of the ensuing malaria season, and a subset of children followed up to the 6-month dry season | ( |
Figure 1Progression from asymptomatic to clinical malaria. Developing clinical malaria following an asymptomatic infection is influenced by host, parasite, and environmental factors. As individuals age and transmission intensity increases, the risk of developing clinical malaria decreases. This is primarily due to the development of acquired immunity in malaria endemic areas where exposure to repeated infection is common. An increase in parasitemia increases the risk of developing clinical malaria, while acquisition of new parasite clones increases the risk of developing symptoms due to lack of protective immunity against the new clones.
A list of selected cytokines and immune cells showing their levels as reported in studies from Africa comparing malaria clinical outcome.
| IL-10 | High | Uganda | Asymptomatic/symptomatic | ( |
| High | Ghana | Asymptomatic/uninfected | ( | |
| High | Mali | Asymptomatic/febrile | ( | |
| High | Gabon | Asymptomatic/mild | ( | |
| IFN-γ | Low | Uganda | Asymptomatic/febrile | ( |
| High | Gabon | Asymptomatic/mild | ( | |
| TNFα | Low | Uganda | Asymptomatic/febrile | ( |
| Low | Uganda | Asymptomatic/symptomatic | ( | |
| Tregs | Low | Uganda | Asymptomatic/febrile | ( |
| Low | Ghana | Asymptomatic/symptomatic | ( | |
| Vδ2+ γδ T cells | Low | Uganda | Asymptomatic/febrile | ( |
| Natural killer cells | Low | Kenya | Asymptomatic/uninfected | ( |
Figure 2Immune modulation during asymptomatic vs. symptomatic malaria infections. The outcome of a malaria infection is influenced by the balance between anti-inflammatory and pro-inflammatory cytokines. Clinical malaria is the result of elevated (+) production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) and increased levels of immune cells (e.g., Vδ2+ γδ, NK cells, and T regs) and the downregulation (–) of anti-inflammatory cytokines (e.g., IL-10). However, with repeated malaria exposure, the immune balance shifts toward an increased production of anti-inflammatory cytokines, leading to asymptomatic infection. The cytokines are encoded by immune genes, thus differential expression of these genes depicts that there is a balance between anti-inflammatory and pro-inflammatory cytokines.